Cheshire drug maker Alexion Pharmaceuticals said it has appointed three new board members, including the former CEO of Astrazeneca, to fill recently created seats.
The company appointed David R. Brennan, M. Michele Burns and Christopher J. Coughlin.
Brennan served as CEO and executive director of fellow pharmaceutical maker Astrazeneca from 2006 to 2012.
Burns is a fellow and strategic advisor at Stanford University’s Center on Longevity and a former senior executive at Marsh & McLennan Cos. and Delta Airlines.
Coughlin is a senior advisor at McKinsey & Co., who formerly held executive roles at Tyco International.
Each will participate in Alexion’s non-employee director compensation plan, which in fiscal 2014 will offer a cash retainer of $80,000 and an equity grant worth $250,000, according to a U.S. Securities and Exchange Commission filing.
Alexion’s board now has 11 seats, up from eight.
Read more
